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Abstract, Concentrations and ex vivo production of 
interleukin 1 j3 (IL-1), tumour necrosis a  (TNF), inter­
leukin 6 (IL-6), interleukin-1 receptor antagonist (IL- 
1RA) and TNF soluble receptors (sTNF-receptors, P55 
and P75) were measured in bronchoalveolar lavage 
(BAL) fluid and blood in 23 HIV-seropositive (HIV-h) 
patients with Pneumocystis carinii pneumonia (PCP) and 
compared with values found in healthy HIV-seronegative 
(HIV-) controls and asymptomatic HIV+ subjects. Con­
centrations of the proinflammatory cytokine IL-1/? were 
increased in BAL fluid of HIV+ patients with PCP 
(184 ± 47pgmL~1) compared with undetectable levels 
in healthy control subjects (P = 0*0001). In plasma of 
these patients higher concentrations of the anti-inflam­
matory cytokine EL-IRA were found during acute PCP 
than after recovery (2-1 ±0-7 vs. 0*5 ± 0*2ngmL_\  
P = 0*01). No correlations could be found between cyto­
kine concentrations and clinical severity of the infection. 
Corticosteroid treatment did not influence cytokine con­
centrations in BAL or blood, nor did it suppress the 
production in alveolar cells. In whole-blood cultures, 
however, lipopolysaccharide (LPS)-stimulated production 
was significantly suppressed for IL-1 (1*3 vs. 5*5 ngmL"1, 
P = 0*009) and for IL-6 (0*6 vs. 2*5 ng mL“\  P  = 0*01). 
The overall data show that in HIV+ patients with PCP 
(similar to what we had found previously in HIV- 
patients with PCP) proinflammatory cytokines are more 
prominently present in BAL, whereas anti-inflammatory 
reaction is predominant in the circulation.
Keywords. Cytokine, HIV, Pneumocystis carinii pneu­
monia, tumour necrosis factor ce, soluble tumour necrosis 
factor receptor, interleukin 1, interleukinl receptor 
antagonist, interleukin 6.
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Introduction
Pneumocystis carinii pneumonia (PCP) is the most fre­
quently occurring severe opportunistic infection in 
patients infected with the human immmunodeficiency 
virus (HIV), Clinical and experimental data suggest that 
CD4+ T lymphocytes are important for protection against 
PCP, although not directly as effector cells [1-3]. 
Macrophages have been shown to interact directly with 
Pneumocystis carinii (.P. carinii) [4—7]. Cytokines are 
likely to be involved as soluble mediators in the host 
defence against P. carinii, as inducers of other mediators, 
as chemo attract ants and as regulators of neutrophil 
adhesion, but their exact role remains to be established.
P. carinii is able to stimulate in vivo and in vitro 
production of tumor necrosis factor-a (TNF) by alveolar 
macrophages [8-13]. In vitro studies suggest that P. 
carinii possesses binding sites for TNF and that this 
cytokine is capable of killing P. carinii [14,15]. In mice, 
TNF and interleukin 1/3 (IL-1) are important for the 
clearance of P. carinii, whereas interleukin 6 (IL-6) 
regulates pulmonary inflammation and antibody 
response during resolution [16-18]. Thus, similar to a 
variety of other infections, IL-1, IL-6 and TNF seem to 
play a role in the pathogenesis of and protection against
PCP.
To investigate the role of these proinflammatory 
cytokines in patients with PCP, we studied the profiles 
of IL-1, TNF, IL-6 and their inhibitors, IL-1 receptor 
antagonist (IL-1RA) and the soluble TNF receptors 
(sTNF-R) in blood as well as in bronchoalveolar lavage 
(BAL) fluid.
Material and methods
Patients
Twenty-three adult HIV-positive (HIV+) patients with 
PCP who underwent BAL according to a standardized 
protocol (see below) at the four participating centres 
(three University Hospitals and one regional referral 
Hospital) were included in the study between October
© 1997 Blackwell Science Ltd
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Table 1. Clinical characteristics of patients and control subjects
HÌV+
PCP
HIV+
asymptomatic
Healthy control 
subjects
Total number 23 25 8
Male (%) 23 (100) 20 (80) 2 (25)
Age (years) (SEM) 35-8 (6-0) 37*4 (8-8) 23-3 (1-6)
Smokers (%) 9(39) 12 (48) 0 (0)
CD4 cells mm”3 (median and range) 30 (10-440) 100 (10-760) ND
Corticosteroids {%) 8 (35) 0 0
Body Lemperature (°C) (SEM) 38-4 °C (1-0) <37-5°C <37*5 °C
W B C x 10-9 L " 1 (SEM) 5-6 (0-5) 4*2 (0*4) 5 ‘0 (0-5)
Per cent Neutrophils (SEM) 76 (3) 57 (2*2) 57 (3-6)
Per cent Monocytes (SEM) 6(5 ) 8 ( 1) 4 (2)
Per cent Neutrophils in BAL (SEM) 15 (2-7) ND 0*9 (0*6)
Per cent Macrophages in BAL (SEM) 68 (4-4) ND 95 (1-1)
Data, except CD4 cells, are given in number and per cent or means and SEM. HIV+, HIV seropositive; PCP, 
Pneumocystis carinii pneumonia; SEM, standard error of the means; ND, not done; BAL, bronchoalveolar lavage 
fluid.
1993 and November 1994. All patients were under the 
care of specialists in internal medicine dealing with 
HIV+ patients. BAL was performed by a chest physician. 
The diagnosis PCP was based on demonstration of P. 
carinii organisms on silver- and/or Giemsa-stained BAL 
specimens [19].
Blood samples for measurements of circulating and ex 
vivo-produced cytokines and inhibitors were taken at the 
time of BAL and after full recovery.
Respiration rate and arterial oxygen pressure (Po2) on 
admission were used as parameters for severity of infec­
tion. In the four participating centres patients were given 
adjunctive corticosteroids when the P02 was equal to or 
less than 8 kPa, a lower threshold than mentioned in the 
NIH consensus [20].
Control subjects
Eight healthy non-smoking subjects who volunteered to 
undergo BAL were used as control subjects [21]. None of 
them used medication or had evidence of lung disease or 
a history of recent respiratory tract infection. Before 
BAL, a blood sample was taken for measurement of 
cytokines and white blood cell count (WBC).
Blood was obtained for cytokine measurements from 25 
asymptomatic ambulant HIV+ individuals with varying 
CD4 counts who visited the HIV clinic of the University 
Hospital Nijmegen. They were the asymptomatic HIV+ 
control group.
Bronchoalveolar lavage
After topical lidocaine anaesthesia of the oropharynx and 
bronchial tree, a flexible fibreoptic bronchoscope was 
introduced into the bronchial tree and, after inspection, 
wedged in a subsegmental bronchus serving the area of 
greatest radiological abnormality. In the control subjects 
the lavage was performed in the right middle lobe. BAL 
was performed by injecting and aspirating 6-8 aliquots 
of 20 mL of sterile saline. In patients most of the BAL
fluid was used for diagnosis, the remaining fluid (in 
general 10-20 mL) for cytokine assessment.
Processing BAL fluid
Immediately after BAL, 30 fiL was taken for cell count 
and cell viability was assessed by trypan blue dye 
exclusion. The remaining fluid was centrifuged at 
500xg for 15min. The supernatant was removed and 
one percentage of bovine serum albumin (Sigma, St 
Louis, MO, USA) was added. The fluid was then filter 
sterilized, aliquoted and frozen at ~80°C until assay.
The pellet was resuspended in Dulbecco’s modified 
Eagle medium at a concentration of 0*5 x lO 6 viable 
macrophages mL-1; 100 (xL was taken for preparing 
cytocentrifuged Giemsa-stained preparations and half 
of the remaining fluid was incubated in 4-mL closed 
polystyrene tubes (Greiner, Alphen, The Netherlands) 
without any addition (unstimulated culture) whereas the 
other half was incubated with lipopolysaccharide (LPS, 
E. coli serotype 055;B5, Sigma) at a final concentration 
of 10 (xg mL” . All incubations were carried out at 37°C 
for 24 h. Following incubation the tubes were centrifuged 
at 1200 x g  for 10 min and the supernatant and cell pellets 
separately frozen at ~80°C until cytokine analysis.
Processing whole blood
Venous blood was drawn from patients and control 
subjects for cytokine assessment in whole blood as 
described previously [22]. Briefly, venous blood was 
collected aseptically into three 5-mL-draw sterile 
vacuum tubes, containing 7*2 mg of lyophilized EDTA 
and 250 ¿¿L of aprotinin (Trasylol 2500 KIU, Bayer, 
Leverkusen, Germany; final concentration 625 
KlEmL“1).
One tube was immediately centrifuged at 1250 xg 
for 10 min. Plasma was transferred to a polypropylene 
tube (Eppendorf, Sarstedt, Numbrecht, Germany) and 
centrifuged at 15000x g  for 1 min to remove platelets.
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Figure 1. Concentrations of cytokines in BAL (A and B) and plasma (C and D) in HIV+ patients with PCP during the acute phase 
(AC) and recovery (REC), in asympytomatic HIV+ subjects (AS) and in healthy control subjects (CO). Bars indicate the medians. 
The asterisks indicate statistical significance (P  ^0*05, Wilcoxon rank-sum test with Kruskal-Wallis chi-square approximation for 
unpaired and signed-rank test for paired samples).
Platelet-poor plasma was pipetted into another sterile 
polypropylene tube and frozen at -80°C until cytokine 
analysis.
In one of the two remaining tubes 50 uL of LPS was 
added (final concentration 10 fxgmL" ) to stimulate 
cytokine production. This tube and the third tube were 
then incubated at 37°C for 24 h. After incubation the 
tubes were centrifuged and the plasma frozen at -80°C as 
described above.
Cytokine assays
Plasma and BAL samples were analysed by specific 
radioimmunoassays for IL-1, IL-1 receptor antagonist 
(IL-1RA) and TNF [23,24]. An Enzyme-linked bind­
ing assay (Hoffman-la Roche, Basel, Switzerland) was 
used for soluble receptors of TNF (sTNF-R;P55, P75), 
and an enzyme-linked immunoassay (ELISA) as 
described before for IL-6 (Inotherapy, Besançon, 
France) [25].
The detection limits of the various assays were: IL-1, 
20pgmL~1; IL-1RA, 800pgmL“1; TNF, 20pgmL-1; 
sTNF-R:P55, BOpgmL“1, P75, 300pgm L''; and IL-6,
20pgmL-1.
Statistical analysis
Values are reported as medians and ranges. Differences 
between groups were analysed with the Wilcoxon rank- 
sum test. For paired samples the signed-rank test was 
used. Correlations between variables were estimated 
with Spearman’s rank correlation coefficient. P-values 
of 0*05 or less were considered significant.
The study was approved by the Hospital Ethics Com­
mittee and informed consent was obtained from all 
patients and healthy control subjects.
Results
Clinical characteristics
Clinical characteristics of patients and control subjects 
are shown in Table 1. PCP prophylaxis was used by four 
patients only (17%), all of them used monthly pentami­
dine. Mean duration of symptoms was 5 (±  5) weeks. 
Mean arterial oxygen pressure was 8*6 (±  1*5) kPa. Eight 
(35%) patients had cytomegalovirus early antigen in 
BAL fluid. Two (9%) patients needed a respirator and 
two (9%) died. Four of the 23 HIV+ patients with PCP 
(17%) had concomitant infections (two had cerebral
© Î997 Blackwell Science Ltd, European Journal o f  Clinical Investigation, 27, 333-339
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cytokines and anti-inflammatory mediators did not 
differ between the acute and recovery phase in HIV+ 
patients with PCP (Fig. ID).
HIV+ patients with PCP had higher circulating con­
centrations of IL-1, IL-1RA and P75 than asymptomatic 
HIV4- patients (124 vs. 98pgmL~1 respectively, 
P -  0002, Fig. 1C; 1*3 vs. 0'SngmL“1, P ~  0-03; 8-5 vs. 
5*8ngmL~\ P = 0*01, Fig. ID).
Compared with healthy control subjects, HIV+ 
patients with PCP had significantly higher concentrations 
of pro inflammatory cytokines (P< 0*002, Fig. 1C) and of 
sTNF-receptors (P< 0-0006, Fig. ID), whereas IL-1RA 
did not differ between the two groups.
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Figure 2. LPS-stimuIated ex vivo  cytokine production in alveolar cells 
(Fig. 2 A) and whole-blood cultures (B) in HIV+ patients with PCP 
during the acute phase (AC) and recovery (REC), in asymptomatic 
HIV+ subjects (AS) and in healthy control subjects (CO). Bars indicate 
the medians, The asterisks indicate statistical significance (P <  0*05, 
Wilcoxon rank-sum test with Kruskal-Wallis chi-square approximation 
and signed-rank test for paired samples).
toxoplasmosis, one cryptococcal pneumonia and one 
salmonella septicaemia). Fourteen patients (61%) were 
given anti-Pneum ocystis carlrtli therapy within 24 h 
before BAL, in the others treatment was started after 
BAL.
Cytokine concentrations in BAL f lu id  and in p lasm a
BAL. BAL was performed in the acute phase of PCP 
and in healthy control subjects. Concentrations of all 
three proinflammatory cytokines were generally higher 
in the acute phase of PCP than in healthy control 
subjects, but significance was only obtained for IL-1 
(184 ±  47pgm L~1 vs. no IL-1 detected, P = 0*0001, 
Fig. 1A). Although concentrations of IL-1RA were high 
in three HIV+ patients (> lOngmL-1), the difference 
with healthy control subjects did not reach statistical 
significance (Fig. IB). Both types of soluble TNF 
receptors were low in BAL fluid.
P lasm a . With the exception of IL-1RA (2*1 ±0*7 in 
the acute phase vs. 0*5 ±0-2ngm L ~l during recovery, 
P  = 0*01], plasma concentrations of proinflammatory
Ex vivo production o f  cytokines
Alveolar cells. During the acute phase of PCP, LPS- 
stimulated production of proinflammatory cytokines by 
alveolar cells of HIV-i- patients did not differ from the 
production of healthy control subjects (Fig. 2 A), whereas 
LPS-stimulated production of DL-1RA was significantly
higher (29*8 ± 4*9 vs. 10*4 ± 1*8, P  = 0*01, Fig. 2 A). Simi­
larly, unstimuiated ex vivo production showed higher 
production of IL-1RA in HIV* patients with PCP, 
median 12*5, range 1*6-95 ngmL“1 vs. median 6*5, range 
O -S^^ngm L”1 in healthy control subjects (P<005).
W hole-blood cultures . LPS-stimulated production of 
IL-6 and TNF was suppressed in the acute phase of PCP, 
and restored during recovery (Fig. 2B.). Although the 
same trend was seen for production of IL-1, the differ­
ence was not significant. Production of IL-1RA tended to 
be higher in the acute phase than during recovery, the 
difference was however, not significant. Compared with 
asymptomatic HIV+ persons, proinflammatory cytokine 
production was slightly lower in the acute phase of PCP 
and higher during recovery. Compared with healthy 
control subjects, LPS-stimulated production of TNF in 
HIV+ patients in the acute phase of PCP was signifi­
cantly suppressed (P = 0*007, Fig. 2B) and IL-1RA pro­
duction capacity increased (P = 0‘01, Fig. 2B).
Unstimulated production of proinflammatory cyto­
kines was higher in HIV+ persons than HIV- control 
subjects and not influenced by the presence of PCP. 
Median concentrations in all HIV+ persons were 
llOpg IL-1 mL”1 (range
102 pg TNF mL“1 (range 60-282p g m L '1), whereas 
concentrations in healthy control subjects were < 20pg 
IL-1 mL“1 (range < 20-280 pgmL“1), and 80pg TNF 
mL-1 (range 60-120pgmL ).
- i< 20-640 pgmL“ 1) and
Effects o f  glucocorticosteroids and/or concomitant 
infections on cytokines in HIV+ patients with PCP
Corticosteroids (40-60 mg of prednisone) were given to 
eight patients, 2-24 h before BAL. Concentrations of 
cytokines in BAL and plasma did not differ from the 15 
patients who were not treated with corticosteroids. LPS- 
stimulated production in alveolar cells also did not differ 
significantly between these two groups (data not shown).
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a e 2. Effect of coiticosteroids on (anti-)inflammatory mediators. Plasma concentrations and LPS-stimulated 
pro uction of (anti ^ inflammatory mediators were measured in two HIV+ patients with PCP before administration
of 40 nig of prednisone (C—) and 24 h after the first dose (C+). Data are presented in ngm L"*1
Plasma concentration Ex vivo production
C - C+ C - C+
Patient A
IL-1 0-12 0*11 31-8 0*80
IL-6 < 0-02 < 0-02 3*36 0-38
TNF 0-11 0-11 3-39 1-20
IL-1RA 1’0 < 0*8 25-3 9*3
sTNF-R, p. 55 3*0 2-5 Below detection limit Below detection limit
sTNF-R, p. 75 7-5 7-25 Below detection limit Below detection limit
Patient B
IL-1 0*10 0’ 13 0-44 012
11-6 0-01 0-02 0*16 0*15
TNF 0-09 0*10 0* 18 0*13
IL-1R A 1*2 1*4 4*6 3 0
sTNF-R, p. 55 4-75 3'5 Below detection limit Below detection limit
sTNF-R, p. 75 11*5 15-0 Below detection limit Below detection limit
However, LPS-stimulated ex vivo  production in whole 
blood showed significantly reduced IL-1 (median 300, 
range 100-7400 pgmL”1) and IL-6 (median 180, range 
30-2960 pgmL- ) production in corticosteroid-treated 
patients as compared with untreated patients (IL-1 
mean 5700, range 700-30300pgmL“1, P = 0-009; and 
IL-6 mean 2060, range 160-4950 ngmL-1, P = 0*01); 
there was no difference in TNF and IL-1RA synthesis.
In two patients circulating concentrations of cytokines 
were not different before and within 24 h after steroid 
administration. However, profound effects were seen on 
whole-blood cytokine production in one patient, whereas 
in the other patient the production was already reduced 
before the administration of corticosteroids (Table 2).
Unexpectedly, cytokine concentrations and production 
in the four HIV+ patients with PCP and another opportu­
nistic infection (cerebral toxoplasmosis in two, cryptococ- 
cal pneumonia in one and salmonella septicaemia in one) 
were not different from those without concomitant infec­
tions (data not shown). We were also unable to show that 
cytomegalovirus in B AL fluid, use of prophylactic penta­
midine inhalations or prior use of anti -Pneumocystis 
carinii therapy affected cytokine profiles
Discussion
HIV+ patients with PCP showed higher concentrations of 
the proinflammatory cytokine IL-1 in BAL fluid than 
healthy control subjects. In the circulation, higher con­
centrations of the anti-inflammatory cytokine IL-1RA 
were found compared with the situation during recovery.
It is tempting to hypothesize that high concentration of 
anti-inflammatory mediators in the circulation ensures 
that the effect of proinflammatory cytokines remains 
limited to the focus of infection. The host is subsequently 
protected against the deleterious systemic effects of 
proinflammatory cytokines, including damage to the
endothelium, shock and mortality. At the site of infec­
tion, these cytokines are important as early response 
mediators regulating cellular function, activating the 
host response against P. carinii and dictating events 
leading to repair of tissue injury. Their presence in 
BAL in patients with PCP is in accordance with the 
findings in in vitro and animal studies showing that TNF 
and IL-1 play a role in the acute phase of PCP 
[12,13,17,18].
Increased concentrations of proinflammatory cyto­
kines in BAL fluid and lungs were also found in HIV- 
negative (HIV-) immunocompromised patients and ster­
oid-treated rats with PCP [21,26], TNF was significantly 
increased in BAL fluid of H IV - patients, IL-6 in BAL 
fluid of rats. In lung homogenates of rats, concentrations 
of IL-I were increased. Thus, in PCP at least one of the 
proinflammatory cytokines is present at the site of infec­
tion, although this is not always the same mediator. Why 
different proinflammatory cytokines are present in BAL 
in the various PCP models (HIV+ patients, immunosup- 
pressed HIV— patients and steroid-treated rats) needs 
further study. The explanation for these differences is 
most probably multifactorial and may reflect different 
underlying immune defects or disease stages. It is 
remarkable that TNF, which is most frequently men­
tioned in relation to HIV and P. carin ii, is only increased 
in BAL in HIV- patients. These data do not corroborate 
findings by Millar et aL [27], who reported increased 
production of TNF by alveolar macrophages in HIV+ 
patients with PCP. Differences in cell populations 
(adherent cells vs. unselected BAL cells in our study), 
incubation time (4 vs. 24 h) and assays (immunoassay vs. 
radioimmunoassay) might be responsible for these dis­
crepancies, Our data are, however, in accordance with 
the results by Kandil et aL [13]. They show that HIV 
infection modulated the response to P. carinii; mono­
cyte-derived macrophages in vitro  infected with HIV and
© 1997 Blackwell Science Ltd, European Journal of Clinical Investigation, 27, 333-339
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co-incubated with P. carinii, produce less TNF and IL-1 
than non-HIV infected cells.
Anti-inflammatory mediators in BAL fluid of HIV- and 
HIV+ patients with PCP show low concentrations of s- 
TNF receptors, whereas IL- IRA is significantly increased 
in the HIV- patients and marginally increased in HIV+ 
patients. Although in some HIV+ patients the increased 
concentrations of IL-1 were accompanied by a local 
increase in IL-1RA, this was not the case in all patients. 
Why in some HIV+ patients with PCP IL-1RA levels were 
not increased in response to the increases in IL-1, as is 
seen in other models of lung injury, needs further study 
and may be explained by the time of sampling or the 
severity of the underlying immune deficiency.
In both HIV+ patients with PCP (this study) and HIV- 
patients with PCP (our previous study, ref. 21) circulat­
ing concentrations of anti-inflammatory mediators were 
higher in the acute phase of PCP than during recovery.
For cytokine patterns in the lung, we had to compare 
HIV+ patients with healthy control subjects because a 
BAL procedure was not considered eligible during 
recovery or in asymptomatic HIV+ persons. For cyto­
kines in the circulation, acute phase was compared with 
recovery in the same patients to match for the presence of 
HIV infection. These data must be interpreted with 
caution because of the use of different control subjects. 
Another problem in our study was the uneven distribu­
tion ol smokers. Smoking has been shown to decrease IL- 
6 concentration in BAL fluid as well as ex vivo produc­
tion of TNF and IL-6 by alveolar macrophages [28], In 
our study 39% of the HIV+ patients with PCP smoked, 
whereas all healthy control subjects were non-smokers. It 
is therefore possible that without this confounding factor, 
concentrations of proinflammatory cytokines in BAL 
fluid in PCP patients would be even higher. Moreover, 
our principle conclusion of divergence of local and 
systemic cytokine profile is supported by similar data 
in H IV- patients with PCP and a rat model [20,26].
Correlations between inflammatory mediators and 
disease activity were not found in our study (data not 
shown). This is in contrast to findings of Benfield et aL 
[29,30], who showed a significant correlation between 
the chemotactic cytokine IL-8 and severity of infection, 
as determined by P02 and BAL neutrophilia. TNF and 
IL-1, which are able to induce IL-8, may have been 
present early in the disease process but may have 
disappeared at the first presentation of the patient. 
From other infectious diseases, e.g. meningococcal 
sepsis, we have found that IL-8 remains much longer 
in the circulation than IL-1 and TNF [31]. The high 
circulating concentrations of proinflammatory cytokines 
in HIV+ patients with PCP should be interpreted against 
the background of cytokine abnormalities in HIV. We 
were able to confirm that HIV infection per se results in 
high plasma concentrations of proinflammatory cyto­
kines and s-TNFRs, and also in increased unstimulated 
proinflammatory cytokine production [32-35]. PCP did 
not further increase these plasma concentrations and 
unstimulated production. Plasma IL-1 concentration in 
the acute phase of PCP in HIV+ patients was not
significantly increased as compared with recovery, but 
was significantly higher than in asymptomatic HIV+ 
persons, which might be explained by the more severe 
HIV infection in the PCP patients; median CD4 count 30 
vs. 100 in the asymptomatic persons (Table 1),
In a recent study, Huang & Eden [36] found dimin­
ished LPS-stimulated production of IL-1 and TNF by 
alveolar cells of AIDS patients with PCP who received 
corticosteroids and suggested that the beneficial effect of 
steroids in PCP may be due to a local reduction in 
proinflammatory cytokine production. In our study, how­
ever, production of proinflammatory cytokines by alveo­
lar cells in HIV+ patients with PCP was not reduced in 
patients who received high-dose corticosteroids 2-24 h 
before BAL. It is therefore improbable that the beneficial 
effect is due to suppression of local production of proin­
flammatory cytokine, unless one assumes that increased 
proinflammatory cytokine production in severe PCP is 
counteracted by suppression of corticosteroids.
Our data from steroid-induced PCP in a rat model do 
not support the latter hypothesis [26] ♦
Both HIV- patients and IiIV+ patients with PCP 
treated with steroids showed suppressed production of 
proinflammatory cytokines in whole-blood cultures in 
the acute phase. In contrast, proinflammatory cytokine 
production was not suppressed in the HIV+ patients with 
PCP, who did not receive steroids. Production in the 
latter group did not differ from that in recovery, nor from 
that in asymptomatic HIV+ individuals. The high 
dosages of corticosteroids were only given to patients 
with Po2 ^  8 kPa. Thus, severe infection could also be 
responsible for suppression of proinflammatory cytokine 
production [31,37,38]. In four of four patients with PCP 
(two HIV+ from the present series and two HIV- [20]), 
blood was taken before and after high-dose corticoster­
oids; in three of these patients we found that cytokine 
production was already suppressed before administration 
of steroids. As all four patients had severe PCP with low 
Po2, severe infection rather than corticosteroids seems to 
lead to down-regulation of systemic proinflammatory 
cytokine production.
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